"Marginal" cardiovascular risk factors: Is there a role for treatment of hyperhomocysteinemia?;Y a-t-il une place pour la thérapeutique de l'hyperhomocystéinémie?

Medecine Therapeutique Endocrinologie

Volumn 3, Issue 5, 2001, Pages 358-363

  Blacher, J ^a   Safar, M ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; HOMOCYSTEINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; HYPERHOMOCYSTEINEMIA; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

EID: 0035188951     PISSN: 12959359     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Homocysteine: The new player in the field of coronary risk
2. Disorders of transsulfuration
3. Homocysteine: A sulph'rous fire
4. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
5. Lowering blood homocysteine with folic acid based supplements meta-analysis of randomised trials
6. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland
7. The natural history of homocystinuria due to cystathionine betasynthase deficiency
8. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arterosclerosis
9. The pathogenesis of coronary artery disease: A possible role for methionine metabolism
10. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis
11. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans
12. Hyperhomocysteinemia induces elastolysis in minipig arteries: Structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide
13. The oxidant stress of hyperhomocysteinemia
14. Hyperhomocysteinemia enhances vascular inflammation and accelerates atheroscierosis in a murine model
15. Homocysteine as a risk factor for vascular disease
16. Homocysteine, diet and cardiovascular diseases. A statement for healthcare professionals from the nutrition committee, American heart association
17. Blood levels of homocysteine and increased risks of cardiovascular disease. Causal or casual?
18. Plasma homocysteine levels and mortality in patients with coronary artery disease
19. Elevated fasting plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
20. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
21. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study
22. The association of elevated plasma homocysteine with progression of symptomatic peripheral arterial disease
23. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease
24. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians
25. Serum total homocysteine and coronary heart disease
26. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men
27. Homocysteine and ischemic heart disease: Results of a prospective study with implications regarding prevention
28. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: A 10-year follow-up
29. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
30. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: The Rotterdam study
31. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham study
32. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women
33. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem
34. Serum total homocysteine and coronary heart disease: Prospective study in middle-aged men
35. Homocysteine and risk of cardiovascular disease among postmenopausal women
36. Plasma homocysteine concentration predicts mortality, in non-insulin-dependent diabetic patients with and without albuminuria
37. Hyperhomocysteinemia increases the risk of death, especially in type 2 diabetes. 5-year follow-up of the Hoorn study
38. Increased plasma homocysteine is an independent predictor of new atherothrombotic brain infarction in older persons
39. Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes
40. Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes
41. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease
42. Homocysteine and major coronary events: A prospective population study amongst women
43. Plasma total homocysteine and cardiovascular and non cardiovascular mortality: The Hordaland homocysteine study
44. Hyperhomocysteinemia. A risk factor or a consequence of coronary heart disease?
45. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke
46. Homocysteine and risk of cardiovascular disease in the multiple risk factor intervention trial
47. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The atherosclerosis risk in communities (ARIC) study
48. A prospective study of folate and vitamine B6 and risk of myocardial infarction in US physicians
49. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery
50. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population-based study
51. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
52. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
53. Plasma total homocysteine concentration and the risk of acute coronary events: The Kuopio ischemic heart disease risk factor study
54. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease
55. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies
56. Fasting plasma homocysteine levels in the insulin resistance syndrome. The Framingham offspring study
57. Interpretations of the Linxian vitamin supplement chemoprevention trials
58. Vitamins and progression of atherosclerosis in hyperhomocysteinaemia
59. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: A randomised, placebo-controlled trial
60. The natural history of vascular disease in homocystinuria and the effects of treatment
61. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease
62. Improved vascular endothelial function after oral B vitamins. An effect mediated through reduced concentrations of free plasma homocysteine
63. Folate-cobalamine interactions
64. Folic acid safety and toxicity: A brief reiew
65. Nutrition and metabolism of vitamins
66. Homocyst(e)ine, diet, and cardiovascular diseases. A statement for healthcare professionals from the nutrition committee, American Heart Association
67. Effects of encainide and flecainide on mortality in randomized trial or arythmia suppression after myocardial infarction
68. World health organization-internal society of hypertension guidelines for the management of hypertension